TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication containing serdexmethylphenidate, a prodrug of dexmethylphenidate, and dexmethylphenidate, a d-threo enantiomer of racemic methylphenidate, which is used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older. Side effects include decreased appetite, nausea, indigestion, weight loss, dizziness, mood swings, increased blood pressure, trouble sleeping, vomiting, stomach pain, anxiety, irritability, and increased heart rate. It was approved for medical use in the United States in March 2021.
=== Remediation === Algae has shown selectivity for strontium in studies, where most plants used in bioremediation have not shown selectivity between calcium and strontium, often becoming saturated with calcium, which is greater in quantity and also present in nuclear waste. Researchers have looked at the bioaccumulation of strontium by Scenedesmus spinosus (algae) in simulated wastewater. The study claims a highly selective biosorption capacity for strontium of S. spinosus, suggesting that it may be appropriate for use in treating nuclear wastewater. A study of the pond alga Closterium moniliferum using non-radioactive strontium found that varying the ratio of barium to strontium in water improved strontium selectivity.
=== Legacy === Baxley, and the film's publicists, touted Stone Cold as the first major biker film since Easy Rider. Henriksen refuted the comparison, as Rider was not intended as a mainstream hit, but called Stone Cold the first "A" example since The Wild One and agreed with Baxley that it might spark a revival of the genre. Around the same time, Harley Davidson and the Marlboro Man was being developed at MGM, while Live Entertainment's Beyond the Law was shot shortly after. None of these films made much of an impact, but the personal praise Henriksen derived from Stone Cold was considered "a huge career boost" by the actor.
== Potential Health benefits == PRP-rich preparations from bovine colostrum have shown possible efficacy against various illnesses including neurodegenerative diseases (such as Alzheimer's), viral infections, and ailments characterized by an overactive immune system, such as allergies, asthma and autoimmune diseases. Some recent research has also indicated possible efficacy in combating obesity.
Sources: en.wikipedia.org
Dicarbonyls react with amines to produce Strecker aldehydes through Strecker degradation. Acrylamide, a possible human carcinogen, can be generated as a byproduct of the Maillard reaction between reducing sugars and amino acids, especially asparagine, both of which are present in most food products.
== Capillary electrochromatography == Capillary electrochromatography (CEC) is an electrochromatography technique in which the liquid mobile phase is driven through a capillary containing the chromatographic stationary phase by electroosmosis. It is a combination of high-performance liquid chromatography and capillary electrophoresis. The capillaries is packed with HPLC stationary phase and a high voltage is applied to achieve separation is achieved by electrophoretic migration of the analyte and differential partitioning in the stationary phase.
The second signal comes from co-stimulation, in which surface receptors on the APC are induced by a relatively small number of stimuli, usually products of pathogens, but sometimes breakdown products of cells, such as necrotic-bodies or heat shock proteins. The only co-stimulatory receptor expressed constitutively by naive T cells is CD28, so co-stimulation for these cells comes from the CD80 and CD86 proteins, which together constitute the B7 protein, (B7.1 and B7.2, respectively) on the APC. Other receptors are expressed upon activation of the T cell, such as OX40 and ICOS, but these largely depend upon CD28 for their expression. The second signal licenses the T cell to respond to an antigen. Without it, the T cell becomes anergic, and it becomes more difficult for it to activate in future. This mechanism prevents inappropriate responses to self, as self-peptides will not usually be presented with suitable co-stimulation. Once a T cell has been appropriately activated (i.e. has received signal one and signal two) it alters its cell surface expression of a variety of proteins. Markers of T cell activation include CD69, CD71 and CD25 (also a marker for Treg cells), and HLA-DR (a marker of human T cell activation). CTLA-4 expression is also up-regulated on activated T cells, which in turn outcompetes CD28 for binding to the B7 proteins. This is a checkpoint mechanism to prevent over activation of the T cell. Activated T cells also change their cell surface glycosylation profile. The T cell receptor exists as a complex of several proteins.
Therefore, the narrative elements of the Makassan people harvesting sea cucumbers, engaging in the production process, and starting to trade, was culturally educational and desirable for the art market.
The Port of Dover is a cross-channel ferry, cruise terminal, maritime cargo and marina facility situated in Dover, Kent, south-east England. It is the nearest English port to France, at just 34 kilometres (21 mi) away, and is one of the world's busiest maritime passenger ports, with 11.7 million passengers, 2.6 million lorries, 2.2 million cars and motorcycles and 80,000 coaches passing through it in 2017, and with an annual turnover of £58.5 million a year. This compares with the nearby Channel Tunnel, the only fixed link between the island of Great Britain and the European mainland, which now handles an estimated 20 million passengers and 1.6 million trucks per year. The modern port facility features a large artificial harbour constructed behind stone piers and a defensive concrete breakwater. The port is divided into two main sections: the Eastern Docks serve as the main cross-channel ferry terminal, while the Western Docks contain a cruise ship terminal and a yacht marina along with cargo facilities. The Port of Dover has a long history and possesses several listed buildings and structures. The port is owned and operated by the Dover Harbour Board, a statutory corporation formed by royal charter in 1606 by King James I. Most of the board members of the Dover Harbour Board are appointees of the Department for Transport. The port has its own private police force, the Port of Dover Police. The current port traffic volumes and urban population categorise Dover as a Large-Port Town.
Sources: en.wikipedia.org
However, there is significant charge transfer between the two materials and, in some cases, hybridization between the d-orbitals of the substrate atoms and π orbitals of graphene, which significantly alter the electronic structure compared to that of free-standing graphene. Boehm et al. coined the term "graphene" for the hypothetical single-layer structure in 1986. The term was used again in 1987 to describe single sheets of graphite as a constituent of graphite intercalation compounds, which can be seen as crystalline salts of the intercalant and graphene. It was also used in the descriptions of carbon nanotubes by R. Saito and Mildred and Gene Dresselhaus in 1992, and in the description of polycyclic aromatic hydrocarbons in 2000 by S. Wang and others. Efforts to make thin films of graphite by mechanical exfoliation started in 1990. Initial attempts employed exfoliation techniques similar to the drawing method. Multilayer samples down to 10 nm in thickness were obtained. In 2002, Robert B. Rutherford and Richard L. Dudman filed for a patent in the US on a method to produce graphene by repeatedly peeling off layers from a graphite flake adhered to a substrate, achieving a graphite thickness of 0.00001 inches (0.00025 millimetres). The key to success was the ability to quickly and efficiently identify graphene flakes on the substrate using optical microscopy, which provided a small but visible contrast between the graphene and the substrate. Another U.S. patent was filed in the same year by Bor Z. Jang and Wen C.
== Usage == The rhizome has a long history of use in Indian Ayurvedic medicine for the treatment of digestive problems. Other uses have been proposed (e.g. for asthma, liver damage, wound healing, vitiligo), but the medical evidence is not yet conclusive. It appears to be relatively safe based on its long history of traditional use. Kutki has hepato-protective properties and thus supports the liver and spleen. It is used in all forms of liver damage, cirrhosis, and inflammation of the liver. It protects the liver against damage from the hepatitis C virus.
The three substrates of this enzyme are crotonic acid, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are butyric acid and oxidised NAD+. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is butanoate:NAD+ Delta2-oxidoreductase. This enzyme is also called enoate reductase. This enzyme participates in phenylalanine metabolism. It has cofactors: flavin adenine dinucleotide and iron–sulfur protein.
Football is the most popular sport in Somalia. Important domestic competitions are the Somalia League and Somalia Cup, with the Somalia national football team playing internationally. In 2017, Somalia won the U-17 title at the CECAFA championship final. Basketball is also played in the country. The FIBA Africa Championship 1981 was hosted in Mogadishu from 15 to 23 December 1981, during which the national basketball team received the bronze medal. In 2013, a Somalia national bandy team was formed in Borlänge. It participated in the Bandy World Championship 2014. In the martial arts, Faisal Jeylani Aweys and Mohamed Deq Abdulle of the national taekwondo team took home a silver medal and fourth place, respectively, at the 2013 Open World Taekwondo Challenge Cup in Tongeren. Additionally, Mohamed Jama has won both world and European titles in K-1 and Thai Boxing. Ramla Ali became the first Somali boxer to compete at the Olympic Games after having previously also won the country's first international gold medal in boxing.
Europe has known almost as much peace as war; and it has owed these periods of peace to the Balance of Power. No one state has ever been strong enough to eat up all the rest, and the mutual jealousy of the Great Powers has preserved even the small states, which could not have preserved themselves.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.